1Associate Professor, Department of Pediatrics, Danylo Halytsky Lviv National Medical University, Ukraine
2Resident Doctor of Department of Vascular and Minimally Invasive Neurology and Neurosurgery, Danylo Halytsky Lviv National Medical University, Ukraine
*Corresponding author: Halyna Bulak, Associate Professor, Department of Pediatrics, Danylo Halytsky Lviv National Medical University, Ukraine
Submission: January 17, 2022; Published: February 16, 2022
ISSN : 2576-9200Volume6 Issue3
Coronavirus Disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus, which is a contagious respiratory virus causing atypical pneumonia COVID-19 in adult and children with Severe Acute Respiratory Syndrome (SARS). The SARS-CoV-2 genome also encodes four structural (S, E, M and N) and up to six accessory (3a, 6, 7a, 7b, 8, and 9b) proteins. The spike protein (S) is further divided into 2 subunits, S1 and S2 that mediate host cell attachment and invasion. Anti-SARS-CoV-2 Monoclonal Antibodies (mAbs) that target the spike protein have been shown to yield clinical benefits in treating SARS-CoV-2 infection. This article represents a clinical case of a 59-year-old man with Coronavirus Disease (COVID-19) and intracerebral haemorrhage, who was treated with the use of monoclonal antibodies bamlanivimab and etesevimab. Equally, it presents a review of these drugs’ application for COVID-19 treatment in adults and children.
Keywords: Coronavirus disease (COVID-19); Monoclonal Antibodies; Bamlanivimab; Etesevimab
Abbreviations: COVID-19: Coronavirus Disease 2019; mAbs: Monoclonal Antibodies; SARS: Severe Acute Respiratory Syndrome; FDA: US Food and Drug Administration; EUA: Emergency Use Authorization; RNA: Ribonucleic Acid; NIHSS: National Institutes of Health Stroke Scale; PCR: Polymerase Chain Reaction; CRP: C-Reactive Protein; CT: Computer Tomography; ESR: Erythrocyte Sedimentation Rate